Immunotherapy: last bullet in platinum refractory germ cell testicular cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy: last bullet in platinum refractory germ cell testicular cancer
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-01-09
DOI
10.2217/fon-2018-0571
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation
- (2017) Stefanie Zschäbitz et al. EUROPEAN JOURNAL OF CANCER
- High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
- (2017) Nabil Adra et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
- (2017) Sasagu Kurozumi et al. Medical Molecular Morphology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
- (2017) Michal Chovanec et al. Oncotarget
- Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
- (2016) S. Zschäbitz et al. ANNALS OF ONCOLOGY
- Learning from the “tsunami” of immune checkpoint inhibitors in 2015
- (2016) Hampig Raphael Kourie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Anti-PD-L1 inhibitor durvalumab in bladder cancer
- (2016) Vicki Brower LANCET ONCOLOGY
- Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
- (2016) S. Shah et al. Cancer Immunology Research
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- Frequent PD-L1 expression in testicular germ cell tumors
- (2015) C D Fankhauser et al. BRITISH JOURNAL OF CANCER
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapies in germ cell tumors
- (2015) Christian M. Squillante et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Testicular Cancer — Discoveries and Updates
- (2014) Nasser H. Hanna et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Action of Immunotherapy
- (2014) Mary L. Disis SEMINARS IN ONCOLOGY
- Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour
- (2011) C. P. Kratz et al. JOURNAL OF MEDICAL GENETICS
- A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation
- (2011) Marlene D Dalgaard et al. JOURNAL OF MEDICAL GENETICS
- TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis
- (2010) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer
- (2010) Clare Turnbull et al. NATURE GENETICS
- Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer
- (2009) Peter A Kanetsky et al. NATURE GENETICS
- Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
- (2009) Xuyang Cheng et al. TRANSPLANTATION
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started